EC
PACB icon

EntryPoint Capital’s Pacific Biosciences PACB Stock Holding History

EntryPoint Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,438
Closed -$46.6K – 906
2024
Q3 		$46.6K Buy
+27,438
New +$45.1K 0.03% 589
2024
Q2 		– Sell
-2,713
Closed -$10.2K – 1427
2024
Q1 		$10.2K Buy
+2,713
New +$15.9K 0.01% 1234

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EntryPoint Capital's PACB Position: Q4 2024 in Review

EntryPoint Capital sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 27,438 shares — an estimated $46.6K sold.

EntryPoint Capital first reported a position in PACB in Q1 2024 and held it in 2 quarters. The position peaked at $46.6K in Q3 2024. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • EntryPoint Capital reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 27,438 Pacific Biosciences shares in Q4 2024, an estimated $46.6K.
  • EntryPoint Capital first reported a position in Pacific Biosciences in Q1 2024 and held it in 2 quarters.
  • EntryPoint Capital's Pacific Biosciences position peaked at $46.6K in Q3 2024.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.